Comparative performance of the GenoLab M and NovaSeq 6000 sequencing platforms for transcriptome and LncRNA analysis

Abstract

Background GenoLab M is a recently established next-generation sequencing platform from GeneMind Biosciences. Presently, Illumina sequencers are the globally leading sequencing platform in the next-generation sequencing market. Here, we present the first report to compare the transcriptome and LncRNA sequencing data of the GenoLab M sequencer to NovaSeq 6000 platform in various types of analysis. Results We tested 16 libraries in three species using various library kits from different companies. We compared the data quality, genes expression, alternatively spliced (AS) events, single nucleotide polymorphism (SNP), and insertions–deletions (InDel) between two sequencing platforms. The data suggested that platforms have comparable sensitivity and accuracy in terms of quantification of gene expression levels with technical compatibility. Conclusions Genolab M is a promising next-generation sequencing platform for transcriptomics and LncRNA studies with high performance at low costs.

Accuracy benchmark of the GeneMind GenoLab M sequencing platform for WGS and WES analysis

“…And WGS library was sequenced on GenoLab M and Novaseq. For GenoLab M, the sequence process was referred to reference 15 . Briefly, the library is denatured to single-stranded and surface-based amplified on the flow cell.…”

“…In October 2020, GeneMind Biosciences Company Limited (GeneMind) launched a new sequencing instrument (GenoLab M) based on their previous work on single molecule sequencer GenoCare™ [ 14 ]. The GenoLab M sequencer employs SBS techniques and reversible termination approaches [ 15 ]. In 2021, the first study using GenoLab M was published [ 15 ], revealing that the GenoLab M is a promising sequencing platform for transcriptomics and LncRNA studies in animal, plant, and human with comparable performance but a lower cost compared to NovaSeq 6000.…”

“…The GenoLab M sequencer employs SBS techniques and reversible termination approaches [ 15 ]. In 2021, the first study using GenoLab M was published [ 15 ], revealing that the GenoLab M is a promising sequencing platform for transcriptomics and LncRNA studies in animal, plant, and human with comparable performance but a lower cost compared to NovaSeq 6000. However, the performance of the GenoLab M platform in other application areas has not yet been released, especially in WGS and WES.…”

Correction to: Comparative performance of the GenoLab M and NovaSeq 6000 sequencing platforms for transcriptome and LncRNA analysis

“…*Correspondence: sunlei@genemind.com † Yongfeng Liu and Ran Han contributed equally to this work. 1 GeneMind Biosciences Company Limited, ShenZhen, China Full list of author information is available at the end of the article…”

“…Following publication of the original article [ 1 ], it was reported that the article erroneously stated that the launch year of NovaSeq 6000 was 2013 instead of 2017.…”